Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janet Scott

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Cancer|June 29, 2004
Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinomaBrian I Rini, Vivian Weinberg, Vanessa Shaw, et al.
The Lancet. Infectious Diseases|April 22, 2014
HIV and schistosomiasis co-infection in African childrenAmaya Bustinduy, Charles King, Janet Scott, et al.
BJU International|April 5, 2007
Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancerJorge A Garcia, Jonathan E Rosenberg, Vivian Weinberg, et al.
IJID Regions|January 15, 2025
Mixed nontuberculous mycobacteria in an immunocompromised patient with probable progressive multifocal leukoencephalopathyChristoffel Opperman, Janet Scott, Janre Steyn, et al.
Frontiers in Global Women'S Health|December 8, 2022
Labor induction information leaflets-Do women receive evidence-based information about the benefits and harms of labor induction?Peter von Dadelszen, Susan Tohill, Julie Wade, et al.
Investigational New Drugs|April 2, 2008
A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?Andrew H Ko, Elizabeth Dito, Brian Schillinger, et al.
Cancer Chemotherapy and Pharmacology|February 5, 2010
A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancerAndrew H Ko, Alan P Venook, Emily K Bergsland, et al.
Breast Cancer Research and Treatment|December 27, 2011
A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancerHope S Rugo, A Jo Chien, Sandra X Franco, et al.
Health Expectations : an International Journal of Public Participation in Health Care and Health Policy|November 7, 2025
What Can We Learn Four Years On? A Multi-Centre Service Evaluation Exploring Symptoms, Functional Impact, Recovery and Care Pathways in Long CovidCassie Lee, Paul Williams, Amiad Abrahams, et al.
Plos One|September 10, 2016
Experimental Treatment of Ebola Virus Disease with BrincidofovirJake Dunning, Stephen B Kennedy, Annick Antierens, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Cancer|June 29, 2004
Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN-01, in renal cell carcinomaBrian I Rini, Vivian Weinberg, Vanessa Shaw, et al.
The Lancet. Infectious Diseases|April 22, 2014
HIV and schistosomiasis co-infection in African childrenAmaya Bustinduy, Charles King, Janet Scott, et al.
BJU International|April 5, 2007
Evaluation and significance of circulating epithelial cells in patients with hormone-refractory prostate cancerJorge A Garcia, Jonathan E Rosenberg, Vivian Weinberg, et al.
IJID Regions|January 15, 2025
Mixed nontuberculous mycobacteria in an immunocompromised patient with probable progressive multifocal leukoencephalopathyChristoffel Opperman, Janet Scott, Janre Steyn, et al.
Frontiers in Global Women'S Health|December 8, 2022
Labor induction information leaflets-Do women receive evidence-based information about the benefits and harms of labor induction?Peter von Dadelszen, Susan Tohill, Julie Wade, et al.
Investigational New Drugs|April 2, 2008
A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?Andrew H Ko, Elizabeth Dito, Brian Schillinger, et al.
Cancer Chemotherapy and Pharmacology|February 5, 2010
A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancerAndrew H Ko, Alan P Venook, Emily K Bergsland, et al.
Breast Cancer Research and Treatment|December 27, 2011
A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancerHope S Rugo, A Jo Chien, Sandra X Franco, et al.
Health Expectations : an International Journal of Public Participation in Health Care and Health Policy|November 7, 2025
What Can We Learn Four Years On? A Multi-Centre Service Evaluation Exploring Symptoms, Functional Impact, Recovery and Care Pathways in Long CovidCassie Lee, Paul Williams, Amiad Abrahams, et al.
Plos One|September 10, 2016
Experimental Treatment of Ebola Virus Disease with BrincidofovirJake Dunning, Stephen B Kennedy, Annick Antierens, et al.
Pageof 3